Since NF1 deficiency leads to the activation of the RAS signaling pathway, patients with AML and overexpression of miR-370 may potentially benefit from additional treatment with either RAS or mTOR inhibitors. The gene discussed is NF1; the disease is acute myeloid leukemia.